FDA approves Alhemo® injection as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophili...
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
bleeds in adults and pediatric patients 12 years of age and older living with hemophilia A or B with inhibitors Results from the pivotal trial showed an 86% reduction in treated spontaneous and traumatic bleeds in patients using Alhemo ® prophylaxis compared to no prophylaxis This approval marks the first subcutaneous injection treatment of its kind for use in this patient population PLAINSBORO, N.J. Dec. 20, 2024 /PRNewswire/ -- Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) approved Alhemo ® (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or B with inhibitors, continuing its more than 35-year commitment to those living with rare bleeding disorders. Alhemo ® is a tissue factor pathway inhibitor (TFPI) antagonist that is dosed in a prefilled, premixed pen for subcutaneous injection (60 mg/1.5 mL, 150 mg/1.5 mL,
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Eli Lilly's obesity drug Zepbound gains approval to treat sleep apnea [USA TODAY]USA TODAY
- Why Viking Therapeutics Tumbled by More Than 10% This Week [Yahoo! Finance]Yahoo! Finance
- Stock market today: Dow, S&P 500, Nasdaq rebound on fresh inflation data to cap volatile week [Yahoo! Finance Canada]Yahoo! Finance Canada
- Yahoo Finance [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk shares tumble as data on weight-loss drug trial disappoints [Financial Times (FT.com) (UK)]Financial Times
NVO
Earnings
- 11/7/24 - Beat
NVO
Sec Filings
- 12/20/24 - Form 6-K
- 12/20/24 - Form 6-K
- 12/18/24 - Form 6-K
- NVO's page on the SEC website